 REDWOOD CITY, Calif., Sept. 08, 2021 GLOBE NEWSWIRE -- Bolt Biotherapeutics, Inc. Nasdaq: BOLT, a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that it has entered into a clinical collaboration and supply agreement with Bristol Myers Squibb NYSE: BMY to investigate Bolt Biotherapeutics BDC-1001 in combination with Bristol Myers Squibbs PD-1 checkpoint inhibitor Opdivo nivolumab. BDC-1001 is a HER2-targeting BoltbodyTM immune-stimulating antibody conjugate ISAC in development for the treatment of patients with HER2-expressing solid tumors. 